Lifeward Ltd Stock Price, News & Analysis

MedRhythms (NASDAQ:LFWD) has appointed Larry Jasinski as its new Chief Executive Officer, effective immediately. Jasinski, former CEO of Lifeward, brings over 30 years of executive leadership in medical devices and neurotechnology. Co-founder Brian Harris transitions to Chief Scientific Officer after successfully leading the company through product development, FDA listings, and CMS benefit category assignments.

The appointment comes as MedRhythms prepares for national expansion of its FDA-listed Class II devices: InTandem® for chronic stroke and Movive™ for Parkinson's disease. Under Jasinski's leadership, the company aims to accelerate market adoption of its prescription music platform and expand access to its neurotherapeutics for walking and mobility improvements.

Jasinski's track record includes leading Lifeward through a successful IPO and securing national reimbursement for the first exoskeleton system for spinal cord injury.

Lifeward (NASDAQ: LFWD), a medical technology company, has closed its previously announced public offering, raising $2.6 million through the sale of 4,000,000 ordinary shares at $0.65 per share. The offering includes warrants to purchase an additional 4,000,000 ordinary shares at an exercise price of $0.65, potentially providing another $2.6 million if fully exercised.

The company plans to use the proceeds for commercial efforts, working capital, and general corporate purposes. H.C. Wainwright & Co. served as the exclusive placement agent for the offering, which was conducted under an effective SEC registration statement.

Lifeward (NASDAQ: LFWD), a medical technology company, has announced the pricing of a $2.6 million public offering. The offering consists of 4,000,000 ordinary shares with accompanying warrants at a combined price of $0.65 per share and warrant.

The warrants will have an exercise price of $0.65, be immediately exercisable, and expire in five years. If fully exercised, they could generate an additional $2.6 million. H.C. Wainwright & Co. is serving as the exclusive placement agent. The company plans to use the proceeds for commercial efforts, working capital, and general corporate purposes, with closing expected around June 26, 2025.

Lifeward (NASDAQ:LFWD) announced a significant legal victory as an Administrative Law Judge (ALJ) ruled that the ReWalk Personal Exoskeleton must be covered by Medicare as a "reasonable and necessary" medical device for individuals with spinal cord injury (SCI). This ruling follows CMS's April 2024 decision establishing a Medicare reimbursement pathway for personal exoskeletons.

The decision reinforces the medical necessity of ReWalk's technology and is expected to influence coverage decisions by commercial insurers. The ReWalk 7, the company's latest innovation and the only personal exoskeleton capable of navigating stairs and curbs, received FDA clearance in March 2025 and is now commercially available in the United States.

Lifeward (NASDAQ: LFWD) has appointed Mark Grant as its new President and CEO, effective June 2, 2025. Grant brings 30 years of commercial leadership experience, particularly from his tenure at Medtronic (2004-2023) where he served as Vice President for the Americas. The outgoing CEO, Larry Jasinski, will serve as Co-CEO through June and remain in an advisory capacity until the end of 2025. Grant's most recent role was as President of Americas and Chief Commercial Officer at IMRA Surgical. As part of his appointment, Grant will receive an inducement award of 400,000 stock options, vesting over four years. The new CEO aims to leverage Lifeward's technical expertise and robotics technology, particularly focusing on the ReWalk exoskeleton's Medicare payment achievement and building a sustainable growth path toward profitability.

Lifeward (NASDAQ: LFWD), a leader in medical technology for people with physical limitations, has announced its participation in the upcoming Sidoti May Virtual Investor Conference. CEO Larry Jasinski and CFO Mike Lawless will represent the company, delivering a corporate presentation on May 21, 2025, at 10:00 AM EDT.

The executives will also host one-on-one meetings with investors during the two-day conference on May 21-22, 2025. Investors can access the presentation through a provided Zoom link and register for both the presentation and one-on-one meetings through the Sidoti website. Registration is complimentary and open to all interested investors, regardless of Sidoti client status.

Lifeward Ltd. (NASDAQ: LFWD) reported Q1 2025 financial results with revenue of $5.0 million, down from $5.3 million in Q1 2024. The company saw mixed performance across segments: AlterG products revenue grew 17% to $3.3 million, while ReWalk Exoskeletons revenue declined. Gross margin improved to 42.2% from 26.4% year-over-year. Operating loss narrowed to $4.9 million from $6.5 million, with net loss per share of $0.46 compared to $0.73 in Q1 2024. Key developments include FDA clearance for ReWalk 7, first commercial insurance approval, new partnerships with CorLife and MYOLYN, and an agreement with BARMER insurance. The company maintains its 2025 revenue guidance of $28-30 million and ended Q1 with $5.7 million in cash.

Lifeward (NASDAQ: LFWD) has completed a three-year research program with the Israel Innovation Authority's Human Robot Interaction Consortium to integrate AI technology into ReWalk Exoskeletons. The company successfully demonstrated a proof-of-concept prototype that combines advanced sensing technologies and AI for autonomous decision-making in different environments. The research, conducted in collaboration with universities and companies, focused on developing social capabilities for robots and improving human-exoskeleton interactions. The program, which ran from May 2022 to April 2025, aimed to make exoskeletons more intuitive, easier to use, and widely accepted through the integration of AI, sensing technologies, and machine vision. Lifeward was one of six companies participating in the consortium.

Lifeward (Nasdaq: LFWD), a global leader in medical technology for people with physical limitations or disabilities, has scheduled its first quarter 2025 financial results release for May 15, 2025, before market opening. CEO Larry Jasinski and CFO Mike Lawless will host a conference call and webcast at 8:30 a.m. EDT to discuss the results.

The earnings call will be accessible via multiple toll-free numbers across the U.S., Germany, and Israel. Investors can also access the webcast through the company's website at GoLifeward.com in the "Investors" section, with an archived version available afterward.